|
1
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Vogelstein B, Fearon ER, Hamilton SR, Kern
SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AM and Bos
JL: Genetic alterations during colorectal-tumor development. N Engl
J Med. 319:525–532. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mäkinen MJ, George SM, Jernvall P, Mäkelä
J, Vihko P and Karttunen TJ: Colorectal carcinoma associated with
serrated adenoma - prevalence, histological features, and
prognosis. J Pathol. 193:286–294. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
O'Brien MJ, Yang S, Huang CS, Shepherd C,
Cerda S and Farraye FA: The serrated polyp pathway to colorectal
carcinoma. Diagn Histopathol. 14:78–93. 2008. View Article : Google Scholar
|
|
5
|
Snover DC, Ahnen DJ and Burt RW: Serrated
polyps of the colon and rectum and serrated polyposisWHO
Classification of Tumors of the Digestive System. Bosman FT,
Carneiro F, Hruban RH and Theise ND: IARC Press; Lyon, France: pp.
160–165. 2010
|
|
6
|
May R, Riehl TE, Hunt C, Sureban SM, Anant
S and Houchen CW: Identification of a novel putative
gastrointestinal stem cell and adenoma stem cell marker,
doublecortin and CaM kinase-like-1, following radiation injury and
in adenomatous polyposis coli/multiple intestinal neoplasia mice.
Stem Cells. 26:630–637. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
May R, Sureban SM, Lightfoot SA, Hoskins
AB, Brackett DJ, Postier RG, Ramanujam R, Rao CV, Wyche JH, Anant S
and Houchen CW: Identification of a novel putative pancreatic
stem/progenitor cell marker DCAMKL-1 in normal mouse pancreas. Am J
Physiol Gastrointest Liver Physiol. 299:G303–G310. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bailey JM, Alsina J, Rasheed ZA,
McAllister FM, Fu YY, Plentz R, Zhang H, Pasricha PJ, Bardeesy N,
Matsui W, et al: DCLK1 marks a morphologically distinct
subpopulation of cells with stem cell properties in preinvasive
pancreatic cancer. Gastroenterology. 146:245–256. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Westphalen CB, Takemoto Y, Tanaka T,
Macchini M, Jiang Z, Renz BW, Chen X, Ormanns S, Nagar K, Tailor Y,
et al: Dclk1 defines quiescent pancreatic progenitors that promote
injury-induced regeneration and tumorigenesis. Cell Stem Cell.
18:441–455. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Nakanishi Y, Seno H, Fukuoka A, Ueo T,
Yamaga Y, Maruno T, Nakanishi N, Kanda K, Komekado H, Kawada M, et
al: Dclk1 distinguishes between tumor and normal stem cells in the
intestine. Nat Genet. 45:98–103. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sureban SM, May R, Ramalingam S,
Subramaniam D, Natarajan G, Anant S and Houchen CW: Selective
blockade of DCAMKL-1 results in tumor growth arrest by a Let-7a
MicroRNA-dependent mechanism. Gastroenterology. 137:649–659,
659.e1-659.e2. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sureban SM, May R, Qu D, Weygant N,
Chandrakesan P, Ali N, Lightfoot SA, Pantazis P, Rao CV, Postier RG
and Houchen CW: DCLK1 regulates pluripotency and angiogenic factors
via microRNA-dependent mechanisms in pancreatic cancer. PLoS One.
8:e739402013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gagliardi G, Goswami M, Passera R and
Bellows CF: DCLK1 immunoreactivity in colorectal neoplasia. Clin
Exp Gastroenterol. 5:35–42. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gao T, Wang M, Xu L, Wen T, Liu J and An
G: DCLK1 is up-regulated and associated with metastasis and
prognosis in colorectal cancer. J Cancer Res Clin Oncol.
142:2131–2140. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ikezono YU, Koga H, Abe M, Akiba J,
Kawahara A, Yoshida T, Nakamura T, Iwamoto H, Yano H, Kage M, et
al: High expression of the putative cancer stem cell marker, DCLK1,
in rectal neuroendocrine tumors. Oncol Lett. 10:2015–2020.
2015.PubMed/NCBI
|
|
16
|
Sureban SM, Madhoun MF, May R, Qu D, Ali
N, Fazili J, Weygant N, Chandrakesan P, Ding K, Lightfoot SA and
Houchen CW: Plasma DCLK1 is a marker of hepatocellular carcinoma
(HCC): Targeting DCLK1 prevents HCC tumor xenograft growth via a
microRNA-dependent mechanism. Oncotarget. 6:37200–37215. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mutoh H, Sashikawa M, Sakamoto H and
Tateno T: Cyclooxygenase 2 in gastric carcinoma is expressed in
doublecortin- and CaM kinase-like-1-positive tuft cells. Gut Liver.
8:508–518. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Vega KJ, May R, Sureban SM, Lightfoot SA,
Qu D, Reed A, Weygant N, Ramanujam R, Souza R, Madhoun M, et al:
Identification of the putative intestinal stem cell marker
doublecortin and CaM kinase-like-1 in Barrett's esophagus and
esophageal adenocarcinoma. J Gastroenterol Hepatol. 27:773–780.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tamoto A, Yashima K, Hosoda K, Yamamoto S,
Kawata S, Ikebuchi Y, Matsumoto K, Kawaguchi K, Harada K, Murawaki
Y and Isomoto H: Protein expression of Fragile Histidine Triad and
cyclooxgenase-2 in serrated neoplasia of the colorectum. Oncol
Lett. 14:3683–3688. 2017.PubMed/NCBI
|
|
20
|
Japanese General Rules for Clinical and
Pathological Studies on Cancer of the Colon: Rectum and Anus.
Japanese Society for Cancer of the Colon and Rectum. 2009.
|
|
21
|
Schlemper RJ, Riddell RH, Kato Y, Borchard
F, Cooper HS, Dawsey SM, Dixon MF, Fenoglio-Preiser CM, Fléjou JF,
Geboes K, et al: The Vienna classification of gastrointestinal
epithelial neoplasia. Gut. 47:251–255. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Saitoh Y, Waxman I, West AB, Popnikolov
NK, Gatalica Z, Watari J, Obara T, Kohgo Y and Pasricha PJ:
Prevalence and distinctive biologic features of flat colorectal
adenomas in a North American population. Gastroenterology.
120:1657–1665. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Jass JR: Classification of colorectal
cancer based on correlation of clinical, morphological and
molecular features. Histopathology. 50:113–130. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Mirzaei A, Tavoosidana G, Modarressi MH,
Rad AA, Fazeli MS, Shirkoohi R, Tavakoli-Yaraki M and Madjd Z:
Upregulation of circulating cancer stem cell marker, DCLK1 but not
Lgr5, in chemoradiotherapy-treated colorectal cancer patients.
Tumour Biol. 36:4801–4810. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Vedeld HM, Skotheim RI, Lothe RA and Lind
GE: The recently suggested intestinal cancer stem cell marker DCLK1
is an epigenetic biomarker for colorectal cancer. Epigenetics.
9:346–350. 2014. View Article : Google Scholar : PubMed/NCBI
|
